Ghrp-6 10mg

▎GHRP-6 Structure

▎GHRP-6 Research

Molecular Background

Growth Hormone-Releasing Peptide-6 (GHRP-6) is a synthetic amidated hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. PubChem lists the stereochemically defined compound under CID 9919153, with the molecular formula C46H56N12O6 and a molecular weight of approximately 873.0 g/mol. Published studies have characterized GHRP-6 as an agonist of the growth hormone-secretagogue receptor (GHS-R1a).[9]

Research Progress

Daniela Risco-Acevedo and colleagues evaluated the combined administration of epidermal growth factor (EGF) and GHRP6 in two preclinical mouse models of cognitive impairment: age-related decline and impairment induced by intracerebroventricular streptozotocin (STZ). C57BL/6 mice were assessed using gait analysis, Y-maze testing, novel object recognition, and qPCR-based gene-expression analysis. The authors reported differences in selected gait and memory-related measurements in the EGF + GHRP6 groups, together with changes in Hmox1, Creb1, Olig1, and Nfkb1 expression. Because GHRP6 was studied together with EGF, the reported findings describe the combination used in the experiment and cannot be attributed to GHRP-6 alone.[1]

Fig1. Behavioral and gait measurements reported after combined EGF + GHRP6 exposure in the age-related mouse model.[1]
The source figure includes body weight, survival, gait parameters, and Y-maze arm-entry measurements. Group sizes, statistical comparisons, and complete experimental procedures are reported in the original publication.[1]

Linlin Wang and colleagues evaluated GHRP-6 in mouse models of lung injury induced by lipopolysaccharide (LPS) or zymosan (ZYM) with platelet-activating factor. Acute and chronic experimental protocols were used to examine pulmonary histology, respiratory measurements, alveolar-capillary barrier-related findings, inflammatory markers, and collagen deposition. The authors reported differences in neutrophilic alveolitis, lung compliance, permeability-related measurements, serum IL-1β, lung-parenchymal integrity, and collagen accumulation in GHRP-6 study groups compared with model controls. These observations were generated in the specific mouse injury models and exposure schedules described in the publication.[2]

Fig2. Pulmonary histology and function-related measurements reported in the LPS-induced mouse model.[2]
The source figure presents the experimental protocol, pulmonary index, H&E-stained lung sections, respiratory rate, minute ventilation, and dynamic lung compliance. Statistical methods and complete study conditions are reported in the original publication.[2]
Daniel Álvarez-Torres and colleagues evaluated GHRP-6 in nervous necrosis virus (NNV) research using E11 fish cells and European sea bass (Dicentrarchus labrax). In vitro, the authors reported differences in cell survival, viral RNA replication, and production of infectious viral particles after GHRP-6 exposure. In the fish experiments, they reported changes in several immune-related genes and lower viral replication in brain samples from GHRP-6 study groups. These findings are specific to fish-cell and aquaculture models and should not be extrapolated to mammalian or human systems.[3]

Fig3. Viral RNA and extracellular infectious-particle measurements reported in RGNNV-infected E11 cells in the cited GHRP-6 study.[3]
The source figure shows absolute viral RNA2 quantification and extracellular infective viral-particle measurements. Statistical comparisons and experimental details are reported in the original publication.[3]

Leandro Rodríguez-Viera and colleagues incorporated GHRP-6 into experimental diets for gilthead sea bream (Sparus aurata) and followed the fish for 97 days. Growth, feed-efficiency, biochemical, hormonal, and tissue-related endpoints were evaluated. The authors reported differences in growth performance, feed efficiency, aerobic-metabolism-related measurements, and plasma GH in the GHRP-6 diet groups under the aquaculture conditions used in the study.[4]
M. Rico and colleagues examined GHRP-6 and GHRH in cultured lamb anterior-pituitary cells and in lambs. The investigators measured GH responses to GHRP-6, GHRH, their combination, and pyridostigmine-associated conditions. In vitro, GHRP-6 produced a lower GH response than GHRH and the combination did not show the same pattern of synergy reported in some other species. In the animal experiment, the authors reported differences in peak GH and area-under-the-curve measurements under selected combination conditions.[5]
In a separate study, M. Rico and colleagues evaluated GHRP-6 in bovine pituitary somatotroph preparations. GHRP-6 was associated with concentration- and time-dependent GH release in the cultured cells, while GHRH and GHRH + GHRP-6 produced larger responses than GHRP-6 alone under several tested conditions. The authors also noted that the interaction between GHRH and GHRP-6 in bovine cells differed from patterns previously reported in rat pituitary cells.[6]

Jázmin Ayman and colleagues studied ghrelin and GHRP-6 in male and female Wistar rats during acute nicotine withdrawal after repeated nicotine exposure. Horizontal and vertical locomotor activity was measured at 12 and 24 hours after the final nicotine administration. The authors reported that nicotine-treated rats showed hyperactivity at the earlier time point and hypoactivity at the later time point, while the ghrelin and GHRP-6 study groups showed different locomotor responses compared with nicotine-only animals. These findings were obtained in a rat withdrawal model and do not establish effects in humans.[7]

Research Limitations

The current GHRP-6 literature includes mouse, rat, fish, ovine, bovine, and cell-based experiments that address substantially different research questions. Results from these systems are not directly interchangeable. Species-specific receptor biology, tissue context, experimental route, exposure schedule, and endpoint selection can materially affect the observations reported. In addition, the cognitive study summarized above evaluated EGF and GHRP6 together, so its findings cannot be used to determine the independent contribution of GHRP-6.[1-7]

Published and regulatory information also remains limited with respect to human safety. FDA has identified GHRP-6 as a bulk substance for which compounded products may present immunogenicity concerns for certain routes because of potential aggregation and peptide-related impurities, and has noted limited safety-related information together with concerns involving cortisol and glucose regulation. These regulatory observations do not describe the identity or performance of a laboratory research material, but they reinforce the need to keep conclusions from preclinical studies within the conditions actually tested.[10]

COCER Peptides presents GHRP-6 solely for laboratory research and analytical use. It is not intended for human or veterinary use. The research described above summarizes findings reported in third-party publications and is not a statement of clinical efficacy, safety, diagnosis, treatment, prevention, or an instruction for use.

▎Relevant Citations

References

[1] Risco-Acevedo D, Subirós-Martínez N, Camacho-Rodríguez H, et al. EGF and GHRP6 Co-Administration Attenuates Cognitive Decline in Preclinical Models: Behavioral and Molecular Evidences[J]. Neurotoxicity Research, 2026,44(4).

DOI:10.1007/s12640-026-00807-0.

[2] Wang L, Berlanga-Acosta J, Yu H, et al. Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis[J]. International Immunopharmacology, 2026,172:116204.
DOI:10.1016/j.intimp.2026.116204.

[3] Álvarez-Torres D, Martínez R, Moreno P, et al. Anti-nervous necrosis virus activity of the growth hormone releasing peptide-6, GHRP-6[J]. Aquaculture International, 2025,33:306.

DOI:10.1007/s10499-025-01987-w.

[4] Rodríguez-Viera L, Martí I, Martínez R, et al. Feed Supplementation with the GHRP-6 Peptide, a Ghrelin Analog, Improves Feed Intake, Growth Performance and Aerobic Diabetes in the Gilthead Sea Bream Sparus aurata[J]. Fishes, 2022,7(1):31.

DOI:10.3390/fishes7010031.

[5] Rico M, Rueda V, Lorenzo M T, et al. Effect of growth hormone-releasing peptide 1-6 on GH secretion-stimulated by GHRH and pyridostigmine in lambs[J]. Journal of Physiology and Biochemistry, 1998,54(2):67-76.

DOI:10.1007/bf03655566.

[6] Rico M, Lorenzo M T, Pazo J A, et al. GHRP-6 in heifer and cow adenohypophisial cells separated by elutriation[J]. Journal of Physiology and Biochemistry, 1999,55(1):33-40.

DOI:10.1007/bf03655604.

[7] Ayman J, Buzás A, Dochnal R, et al. Changes in Locomotor Activity Observed During Acute Nicotine Withdrawal Can Be Attenuated by Ghrelin and GHRP-6 in Rats[J]. Biomedicines, 2025,13(1):143.

DOI:10.3390/biomedicines13010143.

[8] Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration[J]. Frontiers in Endocrinology, 2026,17.

DOI:10.3389/fendo.2026.1822475.

[9] NCBI PubChem. Growth hormone releasing hexapeptide. PubChem CID 9919153.

[10] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: Growth hormone releasing peptide-6 (GHRP-6).

ALL PRODUCTS, ARTICLES, TECHNICAL MATERIALS, PRODUCT DESCRIPTIONS, AND OTHER INFORMATION PROVIDED ON THIS WEBSITE ARE INTENDED SOLELY FOR LEGITIMATE LABORATORY RESEARCH, INFORMATIONAL, AND EDUCATIONAL PURPOSES.

Products offered by Cocer Peptides are intended exclusively for in vitro and laboratory research and are NOT intended for human or veterinary use, human consumption, clinical use, diagnostic use, therapeutic use, compounding, self-administration, injection, or any other form of administration to humans or animals. These products are not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition, nor are they intended to affect the structure or function of the human or animal body. Unless expressly stated otherwise, products offered on this website have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. Any references to published studies, biochemical pathways, molecular mechanisms, or experimental findings are provided solely for scientific discussion and research purposes and do not constitute medical advice, therapeutic claims, dosing guidance, or instructions for use. Purchasers are solely responsible for ensuring that all products are acquired, handled, stored, used, and disposed of in accordance with applicable laws, regulations, institutional requirements, and laboratory safety standards.